Veritas Pharma Stock Probability of Future Pink Sheet Price Finishing Under 0.00

VRTHF Stock  USD 0  0.00  0.00%   
Veritas Pharma's future price is the expected price of Veritas Pharma instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Veritas Pharma performance during a given time horizon utilizing its historical volatility. Check out Veritas Pharma Backtesting, Veritas Pharma Valuation, Veritas Pharma Correlation, Veritas Pharma Hype Analysis, Veritas Pharma Volatility, Veritas Pharma History as well as Veritas Pharma Performance.
  
Please specify Veritas Pharma's target price for which you would like Veritas Pharma odds to be computed.

Veritas Pharma Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Veritas Pharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Veritas Pharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Veritas Pharma generated a negative expected return over the last 90 days
Veritas Pharma has some characteristics of a very speculative penny stock
Veritas Pharma has high likelihood to experience some financial distress in the next 2 years
Veritas Pharma has accumulated 765.63 K in total debt with debt to equity ratio (D/E) of 0.05, which may suggest the company is not taking enough advantage from borrowing. Veritas Pharma has a current ratio of 0.63, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Veritas Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Veritas Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Veritas Pharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Veritas to invest in growth at high rates of return. When we think about Veritas Pharma's use of debt, we should always consider it together with cash and equity.
Net Loss for the year was (2.29 M) with loss before overhead, payroll, taxes, and interest of (112.96 K).
Veritas Pharma has accumulated about 125.27 K in cash with (294.86 K) of positive cash flow from operations.
Roughly 27.0% of Veritas Pharma outstanding shares are owned by insiders

Veritas Pharma Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Veritas Pink Sheet often depends not only on the future outlook of the current and potential Veritas Pharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Veritas Pharma's indicators that are reflective of the short sentiment are summarized in the table below.
Shares Float62.5 M

Veritas Pharma Technical Analysis

Veritas Pharma's future price can be derived by breaking down and analyzing its technical indicators over time. Veritas Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Veritas Pharma. In general, you should focus on analyzing Veritas Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.

Veritas Pharma Predictive Forecast Models

Veritas Pharma's time-series forecasting models is one of many Veritas Pharma's pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Veritas Pharma's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.

Things to note about Veritas Pharma

Checking the ongoing alerts about Veritas Pharma for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Veritas Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Veritas Pharma generated a negative expected return over the last 90 days
Veritas Pharma has some characteristics of a very speculative penny stock
Veritas Pharma has high likelihood to experience some financial distress in the next 2 years
Veritas Pharma has accumulated 765.63 K in total debt with debt to equity ratio (D/E) of 0.05, which may suggest the company is not taking enough advantage from borrowing. Veritas Pharma has a current ratio of 0.63, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Veritas Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Veritas Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Veritas Pharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Veritas to invest in growth at high rates of return. When we think about Veritas Pharma's use of debt, we should always consider it together with cash and equity.
Net Loss for the year was (2.29 M) with loss before overhead, payroll, taxes, and interest of (112.96 K).
Veritas Pharma has accumulated about 125.27 K in cash with (294.86 K) of positive cash flow from operations.
Roughly 27.0% of Veritas Pharma outstanding shares are owned by insiders

Other Information on Investing in Veritas Pink Sheet

Veritas Pharma financial ratios help investors to determine whether Veritas Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Veritas with respect to the benefits of owning Veritas Pharma security.